ProCE Banner Activity

Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Slideset Download
Download this slideset for expert perspectives on best practices in identifying and managing key adverse events commonly associated with BCL-2 and PI3K inhibitors in patients with CLL.

Released: March 17, 2022

Expiration: March 16, 2023

No longer available for credit.

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, Adaptive Biosciences, AstraZeneca, BeiGene, Celgene, Genentech, Janssen, Loxo/Lilly, and Pharmacyclics and funds for research support paid to her institution from AbbVie, AstraZeneca, BeiGene, Genentech, Loxo/Lilly, MingSight, Octapharma, Oncternal, TG Therapeutics, and Verastem.